2 Red Flags That Could Sink Pfizer in 2024
Last year wasn't a particularly good one for (NYSE: PFE). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And clearly, that was shown in our stock price performance, that was very, very bad," Bourla said at the JPMorgan Healthcare Conference last week.
In October, the big pharma company slashed its forecasts for annual coronavirus vaccine and treatment sales due to lower-than-expected demand and announced a cost realignment plan. Meanwhile, the already suffering shares continued to drop, ending the year with a 43% loss. Though there are plenty of reasons to believe this pharmaceutical giant will recover and grow over the long term, this year may continue to present challenges. In fact, here are two red flags that could sink Pfizer in 2024.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 27.62 € bedeuten.
